INTELLIA THERAPEUTICS, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-06: Disclosure Material Terms Of Trading Arrangement; Period 2026-04-01..2026-06-30; Value Rule 10b5-1 Trading Plans The following table describes for the three months ended June 30, 2026 each trading arrangement under which the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securit….
- 2026-05-11: Disclosure Trading Arrangement Duration; Period 2026-01-01..2026-03-31; Value P127D.
- 2026-05-11: Disclosure Material Terms Of Trading Arrangement; Period 2026-01-01..2026-03-31; Value Rule 10b5-1 Trading Plans The following table describes for the three months ended March 31, 2026 each trading arrangement under which the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securi….
- 2026-05-11: Disclosure Trading Arrangement Individual Name; Period 2026-01-01..2026-03-31; Value Michael Dube.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-06 10-Q | Material Terms Of Trading Arrangement | 2026-04-01..2026-06-30 | Rule 10b5-1 Trading Plans The following table describes for the three months ended June 30, 2026 each trading arrangement under which the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securit… | |
| 2026-05-11 10-Q | Trading Arrangement Duration | 2026-01-01..2026-03-31 | P127D | |
| 2026-05-11 10-Q | Material Terms Of Trading Arrangement | 2026-01-01..2026-03-31 | Rule 10b5-1 Trading Plans The following table describes for the three months ended March 31, 2026 each trading arrangement under which the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securi… | |
| 2026-05-11 10-Q | Trading Arrangement Individual Name | 2026-01-01..2026-03-31 | Michael Dube | |
| 2026-05-11 10-Q | Trading Arrangement Individual Title | 2026-01-01..2026-03-31 | (Chief | |
| 2026-05-11 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | Yes | |
| 2026-05-11 10-Q | Trading Arrangement Adoption Date | 2026-01-01..2026-03-31 | March 20, 2026 | |
| 2026-05-11 10-Q | Trading Arrangement Expiration Date | 2026-01-01..2026-03-31 | September 30, 2027 | |
| 2026-04-30 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | It is the policy of the board of directors and the compensation committee not to take material, non-public information into account when determining the timing of equity awards in order to take advantage of a depressed stock price or an anticipated increase in stock price. Similarly, it is our pract… | |
| 2026-04-30 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | No | |
| 2026-04-30 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-30 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | Typically, annual equity awards to our executive officers are made on the first trading day of the month following approval of such awards, which approval generally occurs at the regularly-scheduled board of directors or compensation committee (as applicable) meeting in February. New hire grants to … | |
| 2026-04-30 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | Pay Versus Performance As required by Section 953(a) of the Dodd-Frank Act and Item 402(v) of Regulation S-K, we are providing information about the relationship between executive compensation actually paid to our principal executive officer ( “ PEO ” ) and the average compensation actually paid to … | |
| 2026-04-30 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | (1) The amounts reported represent the “compensation actually paid” to our PEO, computed in accordance with Item 402(v) of Regulation S-K, but do not reflect the actual amount of compensation earned by or paid to our PEO in the applicable year. Dr. Leonard was our PEO for all years presented. In acc… | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$3.80M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $1.98M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $3.30M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$1.25M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$70.24K |
| 2026-04-30 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | (2) The amounts reported represent the average “compensation actually paid” to the NEOs other than our PEO as a group, computed in accordance with Item 402(v) of Regulation S-K. The amounts do not reflect the actual average amount of compensation earned by or paid to such NEOs as a group in the appl… | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.17M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $630.17K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $1.02M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$354.11K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$32.47K |
| 2026-04-30 DEF 14A | Peer Group Issuers Footnote | 2025-01-01..2025-12-31 | (4) Represents the peer group TSR. The peer group used for this purpose is the Nasdaq Biotechnology Index, a published industry index. The comparison assumes $100 was invested for the period starting December 31, 2020, through the end of the listed year. | |
| 2026-04-30 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | (6) Non-PEO NEOs for 2025 include Mr. Dulac, Mr. Basta, Dr. Lebwohl and Dr. Schultes. (7) Non-PEO NEOs for 2024 include Mr. Dulac, Mr. Basta, Dr. Lebwohl, Dr. Sepp-Lorenzino, Mr. Dube and Mr. Goddard. (8) Non-PEO NEOs for 2023 and 2021 include Mr. Goddard, Mr. Basta, Dr. Lebwohl and Dr. Sepp-Lorenzi… | |
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | Compensation Actually Paid and Total Stockholder Return As shown in the graph below, compensation actually paid to our PEO and the average compensation actually paid to the Company’s other NEOs is generally aligned with the Company’s TSR over the five-year period from December 31, 2020 to December 3… | |
| 2026-04-30 DEF 14A | Total Shareholder Return Vs Peer Group | 2025-01-01..2025-12-31 | Compensation Actually Paid and Total Stockholder Return As shown in the graph below, compensation actually paid to our PEO and the average compensation actually paid to the Company’s other NEOs is generally aligned with the Company’s TSR over the five-year period from December 31, 2020 to December 3… | |
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | Compensation Actually Paid and Net Income (Loss) As a clinical-stage company, we did not have any net income during the periods presented and we have not historically considered net income (loss) in evaluating or determining executive compensation. Our net loss increased over the four-year period fr… | |
| 2026-02-26 10-K | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-02-26 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-26 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-26 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-26 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |